Pharmacology Seminar Series

January 19, 202212 pmAgneta Nordberg, MD, PhD
Division of Clinical Geriatrics
Center for Alzheimer Research
Karolinska Institute
Stockholm, Sweden
"Reactive astrogliosis at different states of Alzheimer's disease - relation to other pathology biomarkers and clinical implications"Zoom
January 26, 202212 pmGeorge M. Burslem, PhD
Department of Biochemistry and Biophysics
Perelman School of Medicine
University of Pennsylvania
"Chemical approaches for modulating lysine post-translational modifications"Zoom
February 9, 202212 pmNicole F. Liachko, PhD
University of Washington
Veterans Affairs Puget Sound
Seattle, Washington
"TDP-43 in Alzheimer's disease: pathological correlates and insights from simple models"Zoom
March 9, 202212 pmJamie Walker, MD, PhD
Department of Pathology and Laboratory Medicine
Brain Bank at Biggs Institute for Alzheimer & Neurodegenerative Institute
UT Health San Antonio
San Antonio, Texas
"Resistance to and resilience against Alzheimer's disease neuropathologic change"Zoom
March 24, 20224:00pmInaugural Alan Frazer Lectureship
Peter J. Turnbaugh, PhD
Department of Microbiology & Immunology
University of California, San Francisco
San Francisco, California
"The tiny pharmacists within: how the microbiome impacts the treatment of human disease"409L (LSOM)
March 30, 202212 pm19th Annual Mariann Blum Memorial Lectureship in the Neurosciences
Keri Martinowich, PhD
Departments of Psychiatry and Behavioral Sciences and Neuroscience
Johns Hopkins University School of Medicine
Baltimore, Maryland
"Cell-type and spatially resolved molecular signatures in human brain disorders"409L (LSOM)
April 13, 202212 pmNIH/NIDA T32-Training in Drug Abuse Research: Behavior and Neurobiology Postdoctoral Trainee Mini Symposium
Lawrence M. Carey, IV, Ph.D.

Laboratory of Charles France, Ph.D.

Michael J. Wedemeyer, Ph.D.

Laboratory of Kelly Berg, Ph.D. and Bill Clarke, Ph.D.

Erin Wood, Ph.D.

Laboratory of Nathalie Hill-Kapturczak, Ph.D., & Donald M. Dougherty, Ph.D.
"Carey: Phytocannabinoids as a treatment option for opioid use disorder

Wedemeyer: Characterization of Buprenorphine Antagonism at Human Mu Opioid Receptors

Wood: Heavy drinking behavior trajectory influence drink-refusal self-efficacy: Evidence from a Contingency Management study for DWI arrestees "
444B (LSOM)
April 27, 202212 pmGang Huang, Ph.D.
Department of Cell Systems and Anatomy
Department of Pathology & Laboratory Medicine
UT Health San Antonio
San Antonio, Texas
"Mechanistic and therapeutic implications of pathobiological pseudohypoxia in Myelodysplastic syndroms"444B (LSOM)
May 11, 202212 pmCo-sponsored by the Pain/Immunology Cluster of School of Dentistry
Asaf Keller, PhD
Department of Anatomy and Neurobiology
University of Maryland School of Medicine
Baltimore, Maryland
"Parabrachial nucleus: a nexus of affective pain"444B (LSOM)
May 18, 202212 pmTBD"TBD"
May 25, 202212 pmJessica Ables, MD, PhD
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York
"Effects of diabetes on reward circuitry"444B (LSOM)
June 1, 202212pmMarco Pravetoni, PhD
Department of Psychiatry and Behavioral Sciences
Center for Medication Development for Substance Use Disorders
University of Washington
Seattle, Washington
"Vaccines and antibody-based strategies to treat opioid use disorders and overdose"444B (LSOM)
June 8, 202212pmJames D. Winkler, PhD
Chief Scientific Officer at OnKure Therapeutics
Head, Degrader Technologies, Frontier Medicines
Boulder, Colorado
"Drug discovery with small molecule inhibitors and degraders - Challenges and successes"444B (LSOM)
October 1, 202212PMDr. Frankenstein